Fox Run Management L.L.C. Purchases New Holdings in Insulet Corporation $PODD

Key Points

• Fox Run Management L.L.C. has acquired 4,064 shares of Insulet Corporation (NASDAQ:PODD), valued at approximately $1,067,000 during the 1st quarter.
• Insulet has received a "buy" rating and multiple target price increases from analysts, with an average target price of $330.71 and a consensus rating of "Moderate Buy."
• The company reported a quarterly earnings per share of $1.17, exceeding expectations and reflecting a 32.9% year-over-year revenue growth.

Fox Run Management L.L.C. purchased a new stake in Insulet Corporation (NASDAQ:PODD - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,064 shares of the medical instruments supplier's stock, valued at approximately $1,067,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Sagespring Wealth Partners LLC acquired a new stake in shares of Insulet during the fourth quarter worth approximately $235,000. Mariner LLC lifted its position in Insulet by 8.1% in the 4th quarter. Mariner LLC now owns 6,727 shares of the medical instruments supplier's stock worth $1,756,000 after buying an additional 505 shares in the last quarter. CreativeOne Wealth LLC boosted its stake in shares of Insulet by 332.4% during the 4th quarter. CreativeOne Wealth LLC now owns 3,835 shares of the medical instruments supplier's stock valued at $1,001,000 after buying an additional 2,948 shares during the period. Canada Post Corp Registered Pension Plan purchased a new position in shares of Insulet during the 4th quarter valued at $324,000. Finally, Guggenheim Capital LLC grew its holdings in shares of Insulet by 25.6% during the 4th quarter. Guggenheim Capital LLC now owns 22,355 shares of the medical instruments supplier's stock valued at $5,836,000 after acquiring an additional 4,555 shares in the last quarter.

Insulet Stock Performance

PODD traded up $5.52 during midday trading on Wednesday, reaching $333.00. The company's stock had a trading volume of 618,360 shares, compared to its average volume of 714,102. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. The company has a fifty day simple moving average of $299.94 and a 200 day simple moving average of $285.21. The stock has a market cap of $23.44 billion, a P/E ratio of 101.22, a PEG ratio of 2.74 and a beta of 1.35. Insulet Corporation has a twelve month low of $180.31 and a twelve month high of $333.41.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping analysts' consensus estimates of $0.92 by $0.25. The company had revenue of $649.10 million during the quarter, compared to analyst estimates of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The company's quarterly revenue was up 32.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Research analysts expect that Insulet Corporation will post 3.92 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently issued reports on PODD shares. Royal Bank Of Canada lifted their price objective on Insulet from $330.00 to $350.00 and gave the company an "outperform" rating in a research report on Friday, August 8th. Canaccord Genuity Group raised their price target on Insulet from $331.00 to $353.00 and gave the stock a "buy" rating in a research note on Friday, August 8th. Raymond James Financial reissued an "outperform" rating and issued a $360.00 price target (up previously from $328.00) on shares of Insulet in a research note on Tuesday, May 27th. Wells Fargo & Company increased their price objective on Insulet from $330.00 to $350.00 and gave the stock an "overweight" rating in a report on Friday, August 8th. Finally, Morgan Stanley reiterated an "overweight" rating on shares of Insulet in a research note on Thursday, August 7th. Sixteen investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, Insulet presently has a consensus rating of "Moderate Buy" and a consensus target price of $330.71.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.